In this regard, a crucial study has demonstrated that targeting CXCL12 from FAP+ CAFs with plerixafor (AMD3100) synergizes with anti-PD-L1 treatment in pancreatic cancer [157]. Here, CXCL12 is linked to pancreatic neoplasm.